Erythropoietin for HCV May Lack Clinical Benefit : The drug's expense along with its unproven survival benefit are enough to signal caution in many settings.

“Hopefully, future trials will address these questions,” he said.

Dr. Yoshida's review was summarized in the Annals of Pharmacotherapy (2007;41:268–75).

He declared no financial interest in any hematopoietic agent.